Amlodipine/rosuvastatin/telmisartan - YuhanAlternative Names: Amlodipine/telmisartan/rosuvastatin; Rosuvastatin/amlodipine/telmisartan; Rosuvastatin/telmisartan/amlodipine; Telmisartan/amlodipine/rosuvastatin; Telmisartan/rosuvastatin/amlodipine; YH 22189; YHP 1604
Latest Information Update: 15 Nov 2016
At a glance
- Originator Yuhan
- Class Antihyperlipidaemics; Antihypertensives; Benzimidazoles; Benzoates; Dihydropyridines; Fluorobenzenes; Ischaemic heart disorder therapies; Pyrimidines; Small molecules; Sulfonamides
- Mechanism of Action ACE inhibitors; Angiotensin type 1 receptor antagonists; Calcium channel antagonists; HMG-CoA reductase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Hyperlipidaemia; Hypertension